Jessica Merrill
Senior Editor
Latest From Jessica Merrill
The Life Of A Blockbuster
The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.
Gene Therapy Q1 Roundup: The Struggle Is Real
Vertex and bluebird compete for sickle cell patients, BioMarin talks about divesting Roctavian, and Sarepta warned that sales of Elevidys will plateau with a narrow label.
Teva Starts The Year With Phase III Data And Growth
Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.
With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way
The company initiated a rolling NDA submission for suzetrigine for acute pain, positioning the drug for a launch in 2025.
Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy
Longtime pharmaceutical industry analyst Andrew Baum will join Pfizer’s executive leadership team.
Dupixent COPD Approval Could Be Delayed, Regeneron Cautions
The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.